Xcout IntelRevelation Biosciences, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Revelation Biosciences, Inc. among biotechnology companies — ranked by similarity to what Revelation Biosciences, Inc. actually does, not by market-cap band.
Subscribe to see Revelation Biosciences, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Revelation Biosciences, Inc. at a glance
Revelation Biosciences, Inc. is a biotechnology company headquartered in San Diego, United States. It is publicly listed (REVB) with a market capitalisation of $3.7M. Xcout tracks 19 named people at Revelation Biosciences, Inc., including James Rolke (Chairman & Chief Executive Officer).
Revelation Biosciences, Inc. leadership
- James RolkeChairman & Chief Executive Officer
- Chester Stanley ZygmontChief Financial Officer & Corporate Secretary
- Sandra VedrickVice President of Human Resources & Investor Relations
- Carol OdleSenior Director of Clinical Projects
- Andreas TypaldosDirector
- Anthony HayesDirector
13 more named people on record for Revelation Biosciences, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Revelation Biosciences, Inc. competitors
Ranked by semantic similarity — how close each company is to Revelation Biosciences, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Life Sciences
R1 Therapeutics is a renal-focused biotech company developing innovative, first-in-class, category-defining therapeutics for patients with kidney disease. Headquartered in San Francisco with additional offices in San Diego and Raleigh, the company started with lead asset AP306.
Biotech
Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene. This modulation is strategically aimed at activating immune cells for oncology treatments and suppressing them for autoimmune conditions. Its therapeutic pipeline and product development are currently in their initial phases. Established in 2012, the firm operates from its headquarters in La Mesa, California.
Biotech
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Biotech
Rejuvenate Bio, Inc. is a biotechnology company founded in 2019 and headquartered in San Diego, United States, specializing in innovative gene therapy applications.
Biotech
AXIM Biotechnologies, Inc. specializes in the creation and distribution of advanced diagnostic solutions for healthcare, focusing on critical areas such as SARS-CoV-2 (COVID-19), ocular health, and cancer treatment. The company is currently developing rapid diagnostic assays that quantify functional neutralizing antibodies, which are essential for preventing the SARS-CoV-2 virus from attaching to human cells. Additionally, it offers serological diagnostic tests designed to detect neutralizing antibodies, thereby assessing the body's adaptive immune response to the virus, and is developing tests to identify inflammation biomarkers for the effective management of COVID-19 patients. For eye health, AXIM is pioneering quick, quantitative tear tests to measure Matrix metalloproteinase-9, an inflammatory marker associated with dry eye disease. In its oncology pipeline, the firm is advancing SBI-183, an anti-metastatic compound engineered to inhibit tumor cell growth and block the spread of cancer, as well as SPX-1009, another anti-metastatic therapy aimed at determining the levels of quiescin sulfhydryl oxidase I. Established in 2010, the company was formerly known as Axim International Inc. before officially changing its name to AXIM Biotechnologies, Inc. in July 2014, and it is headquartered in San Diego, California.
Similar biotechnology company
Gemma Labs Inc. (GEMMABio) is a biotechnology company that develops gene therapies for rare diseases using next-generation AAV technology. The company focuses on programs targeting motor neuron disorders, skeletal conditions, and cardiomyopathies to serve the rare disease community.
Biotech
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Biotech
Resverlogix Corporation is a biotechnology firm currently in advanced clinical development, concentrating on developing treatments for illnesses where existing medical solutions are inadequate. The company's leading therapeutic compound is apabetalone (RVX-208), a selective small molecule designed to inhibit bromodomain and extra-terminal proteins. This compound is presently undergoing pivotal Phase III clinical trials for patients afflicted with conditions such as cardiovascular disease, diabetes, various stages of kidney disease (including end-stage renal disease), and neurodegenerative disorders. Furthermore, Resverlogix Corp. has forged an alliance with Eversana Life Science Services, LLC to support the forthcoming commercial rollout of apabetalone as a treatment for COVID-19 across the United States and Canada. The company's main office is located in Calgary, Canada.
Similar biotechnology company
Foment Bio, Inc. is a biotechnology company developing non-viral, transient gene therapy constructs designed to stimulate in vivo regenerative exosome production. The company's therapies aim to restore tissue microvasculature, resolve inflammation, and rescue cells to treat age-related and cardiometabolic conditions such as heart failure, chronic kidney disease, erectile dysfunction, and impaired wound healing.
Similar biotechnology company
XORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney diseases, including specific pipeline candidates for gout and other conditions.
Biotech
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Revelation Biosciences, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Revelation Biosciences, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →